On October 8, Direxion Daily S&P Biotech Bull 3x Shares fell 8.24% in regular trading, trading at $209.175 per share, with turnover of $81.3021 million.

The fund provides triple leveraged exposure to the S&P Biotechnology Select Industry Index, significantly amplifying the underlying index's pullback. As of October 6, the index itself declined 3.35% to 11,811.77, while this leveraged product experienced a much deeper drawdown.

Recent sentiment in the biotechnology sector has deteriorated amid resurgent concerns over US interest rate expectations. High-duration, pre-revenue biotech names remain vulnerable to tighter monetary policy, and renewed rate-hike fears have triggered pronounced retracements in leveraged biotech products over consecutive sessions.

The fund invests at least 80% of its net assets in financial instruments and securities of the index, ETFs that track the index, and other instruments providing daily leveraged exposure to the index or its tracking ETFs. The index measures the performance of the biotechnology sub-industry based on the Global Industry Classification Standards.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)